Arbuthnot Commercial Asset Based Lending (ACABL) has provided a comprehensive funding package to support Alinea and strategic investor Richard Hale’s investment in Serchem Limited, a decontamination and hygiene chemical producer.
The flexible asset-based lending package includes a revolving receivables facility to fund ongoing working capital for future growth, along with property and cash flow term loans to create additional headroom.
Established in 1981, Serchem produces decontamination and hygiene chemicals for the healthcare and facilities management industries in the UK and internationally. ACABL will work closely with the management and investor teams to support Serchem through its next growth phase.
Alison Arnold, commercial director & shareholder at Serchem Limited, said: “The team at Arbuthnot Commercial ABL understood what we were looking to achieve and structured a deal that would help us realise our goals as quickly as possible.
“The transaction with Arbuthnot puts us in an excellent position to drive further growth, working alongside a carefully selected group of experienced investors and further strengthening our customer relationships and position in the market. We look forward to working with both our investors and Arbuthnot as we embark on this next phase of growth.”
Oliver Wadlow, director at Alinea, aded: “We wanted to work with a collaborative funder that we know could deliver and therefore selected Arbuthnot Commercial ABL because of the track record of certainty they bring to transactions. They took a holistic view of the business and were very proactive and pragmatic to work with. We are excited to see the investor team and current shareholders work together, enabling them to build on the strong platform they have developed and capitalise on their immediate project opportunities.”
Andrew Rutherford, commercial director at Arbuthnot Commercial Asset Based Lending Limited, concluded: “We were delighted to support this well-funded deal, led by investors we know well.
“Serchem has a leading role in developing and manufacturing hygiene and decontamination products for the NHS, and we are excited at this opportunity to structure a flexible funding package that will help them drive further growth and success.
“This investment provides the best of both worlds; the opportunity for the existing directors to realise some value and the additional support of committed and knowledgeable investors to maximise opportunities for further growth and development.”
